PFS is an essential endpoint in clinical trials for gynecological cancers. It helps in evaluating the efficacy of _new therapies_ and treatment protocols. Unlike overall survival (OS), which measures the time from diagnosis to death from any cause, PFS specifically looks at whether the cancer has _progressed_ or not. This makes it a more sensitive indicator for early efficacy assessment.
